GVHD

Expanded access of Ruxolitinib cream to treat a single patient with cGVHD

Incyte Study ID:
I 18424-22-02
CT.gov ID:
NCT03147742
Eudra ID:
N/A
Sponsor:
Incyte Corporation
Collaborator:
N/A
Study Contact Information:
1.855.463.3463 or [email protected]
Recruiting
Subscribe to Updates

Clinical Study Purpose

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

Clinical Study Summary

MEDICAL CONDITION(S)
  • GVHD
    • PRODUCT
  • Drug: Ruxolitinib
    • COLLABORATORS
    N/A
    DATE
    N/A - N/A
    TYPE
    Expanded Access
    PHASE
    N/A
    SEX
    Female & Male
    AGE
    NA+ years
    ACCEPTS HEALTHY VOLUNTEERS

    Key Inclusion and Exclusion Criteria

    Inclusion Criteria

    Exclusion Criteria

    Clinical Study Locations

    No locations found.

    Protocol Summary

    Incyte Study ID:
    I 18424-22-02
    Primary Purpose:
    N/A
    Allocation:
    N/A
    Study Design:
    N/A
    Masking:
    N/A
    Interventions:
    Drug
    Enrollment:
    Primary Outcome
    Open
    Secondary Outcome
    Open